Skip to content

MAZE MAZE EBITDA

EBITDA at other companies

Septerna, Inc. logo
Septerna, Inc.SEPN
-$12.88M+49.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$52.98M-147%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
-$57.87M-66.5%
Zymeworks logo
ZymeworksZYME
-$45.98M-99.8%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$90.3M-49.2%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Calculated from MAZE’s reported figures.

$26.6Mebit+
$444.0KDepreciation Depletion & Amortization
=-$26.11M

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's EBITDA?
MAZE (MAZE) reported EBITDA of -$26.11M in Q1 2026.
How has MAZE's EBITDA changed year-over-year?
MAZE's EBITDA increased by 24.8% year-over-year, from -$34.72M to -$26.11M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.